Navigation Links
Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
Date:8/4/2009

BEIJING, Aug. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers received their first shot of the vaccine and, during the three day observation period, the preliminary tests indicated that the A/H1N1 influenza vaccine is safe and reliable in humans.

The clinical trial began on July 22, 2009 and a total of 1,614 volunteers, including 101 elders, 706 adults, 404 juvenile and 403 children, had received the first shot of the vaccine through July 25. During the three-day observation period, none of the volunteers participating in Sinovac's clinical tests exhibited any sign of severe adverse reactions. Total adverse event rate is 11.8%, which is similar to that of seasonal influenza vaccine. The adverse events were all mild and transient. The most severe symptom was pain at the site of injection.

This clinical trial is organized by China's Center for Disease Control (CDC), and undertaken by Beijing CDC. The Ministry of Health (MOH) and State Food and Drug Administration (SFDA) are paying close attention to this clinical trial. Deputy Director General of MOH Disease Control Department, Donglou Xiao, Director of SFDA Registration Section, Wei Zhang, and other relevant experts visited the clinical trial site to observe the clinical trial. In June 2009, the Beijing municipal government(1) made its first purchase of Panflu from Sinovac, with an initial order of four million doses that are expected to be delivered by the end of September 2009.

Consistent with prior years' practices, Sinovac's seasonal influenza vaccine was released by China SFDA and commercially launched at the end of July 2009.

    (1) Sinovac's press release date
'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer
2. REVISED: BrainCells Inc. Expands Series B Financing to $50 Million
3. Sinovac Announces Postponement of Annual General Meeting
4. Sinovac Requests Extension for Annual Shareholders Meeting
5. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
6. Sinovac Closes $9.75 Million Private Placement
7. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
8. Sinovac Announces Adjournment of Annual General Meeting
9. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
10. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
11. Sinovac Biotech Holds Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... MO (PRWEB) August 21, 2014 ... service biopharmaceutical contract development and manufacturing organization (CMO) ... Progenics Pharmaceuticals, Inc., an oncology company focused on ... treating cancer, to manufacture the anti-prostate specific membrane ... ADC product candidate. Under the agreement the ...
(Date:8/20/2014)... N.C. , Aug. 20, 2014 ... research services located in Raleigh, NC ... Bradford Evans as Vice President of Administration. ... Brad will oversee all corporate processes, including their ... joining Clintrax Global, Brad worked as an HR ...
(Date:8/20/2014)... in measuring vibrational motion of a single molecule with ... of a single molecule differs from the behaviour of ... at the University of California, Irvine, where post-doctoral researcher ... a visiting fellow under professor Vartkess A. Apkarian, whose ... lead by Professor Eric O. Potma. The results of ...
(Date:8/20/2014)... BURLINGTON, Mass. , Aug. 20, 2014  Decision Resources Group ... , Russia , India ... approximately $1.6 billion in 2013, roughly equal to the size of ... forward, however, the BRIC market will experience much faster growth as ... the aging population. Other key findings from Decision Resources ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Clintrax Global, Inc. Announces Addition to Executive Team 2Seeing a molecule breathe 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... and LEXINGTON, Massachusetts, August 25, 2011 Shire ... specialty biopharmaceutical company, today announced that the U.S. Food and ... (icatibant injection) for treatment of acute attacks of hereditary ... "Until now, HAE patients faced challenges gaining rapid ...
... CBI, a division of Advanstar Communications, is pleased ... Tufts Center for the Study of Drug Development and ... the keynote speaker at their Pharma/Bio Forum on Preclinical ... at the Hyatt Harborside in Boston, MA. Dr. Kaitin ...
... school science teachers will explore the nanotechnology field at ... build interest in science and engineering. ... of Engineering a $429,000 grant to fund "Innovations in ... Starting next summer, selected middle and high school ...
Cached Biology Technology:FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 2FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 3FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 4FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 5FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 6Dr. Ken Kaitin, Tufts CSDD, Keynotes Preclinical Conference 2University of Houston receives NSF grant for high school teachers program 2
(Date:8/21/2014)... involves the pancreas digesting itself resulting in severe abdominal ... UK around 20,000 patients are diagnosed with the disease ... and treatment is restricted to intravenous fluid and nutritional ... of Life Sciences, who led the research, said "The ... gall stones and excessive alcohol intake combined with a ...
(Date:8/20/2014)... SALT LAKE CITY Researchers at Huntsman Cancer Institute (HCI) ... mutated forms of the gene that encodes BCR-ABL, the ... (CML). According to the American Cancer Society, nearly 6,000 ... , Drugs already in use, called tyrosine kinase inhibitors ... disease. They do not cure CML but control it ...
(Date:8/20/2014)... Scientists from the University of Tbingen, Arizona State University, ... and Public Health Institute (Swiss TPH) isolated Mycobacterium ... at least 1000 years old. The pathogen is a ... only occasionally causes disease in humans today. These researchers ... the Peruvian coast. "The link to sea lions was ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... second most common cause of childhood blindness in the ... earlier than or at 28 weeks gestational age. The ... the retina of the eye. ROP risk increases with ... Brigham and Women,s Hospital (BWH) suggests that the antioxidant, ...
... young researchers were named Pew Scholars in the Biomedical ... join a prestigious community that includes Nobel Prize winners, ... Research Award. "During these challenging budgetary ... harder for scientists to obtain, we are proud to ...
... heavy rain, the lid of Nepenthes gracilis ... shelter on its underside directly into the fluid-filled pitcher, ... Wednesday 13 June, in the journal PLoS ONE ... a source of nutrients, enabling them to colonise nutrient-poor ...
Cached Biology News:Antioxidant shown to reduce blindness risk in extremely premature babies 222 of America's most promising scientists selected as Pew Biomedical Scholars 222 of America's most promising scientists selected as Pew Biomedical Scholars 3Pitcher plant uses rain drops to capture prey 2
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
...
Biology Products: